AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study of AZD3470, a PRMT5 Inhibitor, in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors
- First Posted Date
- 2023-11-14
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 234
- Registration Number
- NCT06130553
- Locations
- 🇪🇸
Research Site, Madrid, Spain
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1145
- Registration Number
- NCT06129864
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
HER2 TREAT Study: Retrospective Study to Estimate the Prevalence of HER2-low in Unresectable and/or Metastatic Breast Cancer Patients Who Progress on Anti-Cancer Therapy Identified as HER2-Negative From Patient Medical Records in The Gulf Cooperation Council
Completed
- Conditions
- First Posted Date
- 2023-11-09
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 517
- Registration Number
- NCT06125314
- Locations
- 🇦🇪
Research Site, Dubai, United Arab Emirates
Non-alcoholic Steatohepatitis Registry Platform Study
Recruiting
- Conditions
- First Posted Date
- 2023-11-09
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2500
- Registration Number
- NCT06123858
- Locations
- 🇨🇳
Research Site, Zhengzhou, China
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2023-11-08
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 95
- Registration Number
- NCT06122714
- Locations
- 🇺🇸
Research Site, Brooklyn, Maryland, United States
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1800
- Registration Number
- NCT06120491
- Locations
- 🇬🇧
Research Site, Truro, United Kingdom
Chronic Kidney Disease Registry Platform Study
Recruiting
- Conditions
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5000
- Registration Number
- NCT06117852
- Locations
- 🇨🇳
Research Site, Zigong, China
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Subcutaneous AZD6912 in Healthy Participants
- First Posted Date
- 2023-11-03
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 64
- Registration Number
- NCT06115967
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1728
- Registration Number
- NCT06112379
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-10-31
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 750
- Registration Number
- NCT06109779
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath